Evidence map›Paper›PMID 20833372›Full record

ArticleCell host & microbe2010

Stopping HPVs dead in their tracts.

Joseph J Carter, Denise A Galloway

Open access · bronzeAbstract readComment
PubMed Publisher
In one paragraph

Article in Cell host & microbe, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 86% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors at 1 institution in 2 countries.

Joseph J CarterFred Hutchinson Cancer Research Center, Seattle, WA, USA. jcarter@fhcrc.org
Denise A Galloway
Fred Hutch Cancer Center · US

Funding

HPV CAPSID ANTIBODIESR01AI038382 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI GALLOWAY, DENISE A. · 1995 to 2020
$4.4M
NIAID NIH HHS R01 AI038382
6 · The paper itself

Abstract

Vaccines are currently available to prevent infection of the genital tract and subsequent disease for some human papillomavirus (HPV) types, and attempts to develop broadly cross-reactive HPV vaccines are progressing. A recently developed murine model of cervicovaginal HPV infection examines the mechanisms by which antibodies prevent infection in vivo.

Identifiers

PMID20833372
OpenAlexW2076836645

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.